C12N 2730/10171
Demonstrated in vivo effect
C12N2730/10171 (Demonstrated in vivo effect) appears on 46 US grants and 79 published applications in this corpus.
Search patents in C12N- Granted patents
- 46
- Published applications
- 79
- Assignees
- 52
- Inventors
- 135
- Latest grant
- 16 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2012 | 0 | 2 |
| 2013 | 0 | 2 |
| 2014 | 1 | 3 |
| 2015 | 0 | 3 |
| 2016 | 6 | 16 |
| 2017 | 3 | 13 |
| 2018 | 8 | 7 |
| 2019 | 6 | 8 |
| 2020 | 6 | 4 |
| 2021 | 1 | 3 |
| 2022 | 6 | 5 |
| 2023 | 3 | 1 |
| 2024 | 3 | 7 |
| 2025 | 3 | 4 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Therapeutic vaccine for hepatitis b virus (HBV) using the HBV core antigen16 Dec 2025US 12,496,339 B2Abacus Bioscience, Inc.
- Universal vaccine platform25 Mar 2025US 12,257,302 B2Arizona Board of Regents on behalf of Arizona State University
- Methods and compositions for the treatment of hepatitis B infection21 Jan 2025US 12,202,862 B2Melbourne Health
- Vaccines against hepatitis B virus5 Mar 2024US 11,918,645 B2Altimmune UK Limited
- Therapeutic vaccine for Hepatitis B virus (HBV) using the HBV core antigen30 Jan 2024US 11,883,488 B2Abacus Bioscience, Inc.
- Compositions and methods for treating genetic disorders9 Jul 2026US 2026/0191908 A1
- Methods and compositions for the treatment of hepatitis b infection30 Oct 2025US 2025/0333450 A1Melbourne Health
- Glycosyl-modified fusion protein, nucleic acid molecule, expression vector, host cell and applications thereof8 May 2025US 2025/0144194 A1Kaimi Biomedicine (Chengdu) Co., Ltd.
- Glycosyl-modified fusion protein, nucleic acid molecule, expression vector, host cell and applications thereof8 May 2025US 2025/0144202 A1Kaimi Biomedicine (Chengdu) Co., Ltd.
- Methods and compositions for the treatment of hepatitis b infection8 May 2025US 2025/0145669 A1Melbourne Health
Most cited
By later US patents
- Derivatives and methods of treating hepatitis B infections10US 9,527,845 B2Novira Therapeutics, Inc. · 2016
- Derivatives and methods of treating hepatitis B infections9US 9,518,057 B2Novira Therapeutics, Inc. · 2016
- Derivatives and methods of treating hepatitis B infections9US 9,550,779 B2Novira Therapeutics, Inc. · 2017
- Compositions, comprising improved IL-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same8US 9,272,024 B2The Trustees of the University of Pennsylvania · 2016
- Compositions, comprising improved Il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same7US 9,981,036 B2The Trustees of the University of Pennsylvania · 2018